June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Determining the Efficacy of a Novel Targeted Therapeutic Approach Against Herpes Simplex Virus-1 in an Organotypically Cultured Corneal Model
Author Affiliations & Notes
  • Paul Park
    Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL
  • Tibor Valyi-Nagy
    Pathology, University of Illinois at Chicago, Chicago, IL
  • Deepak Shukla
    Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL
    Microbiology and Immunology, University of Illinois at Chicago, Chicago, IL
  • Footnotes
    Commercial Relationships Paul Park, None; Tibor Valyi-Nagy, None; Deepak Shukla, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5988. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Paul Park, Tibor Valyi-Nagy, Deepak Shukla; Determining the Efficacy of a Novel Targeted Therapeutic Approach Against Herpes Simplex Virus-1 in an Organotypically Cultured Corneal Model. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5988. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Herpes simplex virus-1 (HSV-1) infection of the cornea is the leading cause of infectious blindness in the developed world. Recent studies in cell culture and mouse models have suggested that a peptide blocking 3-O-sulfated heparan sulfate (3-OS-HS) can effectively inhibit HSV-1 infection of the corneal epithelium. This study aimed to assess the potential of an ex vivo organotypically-cultured corneal model to detect an inhibitory role of these peptides against HSV-1 infection.

Methods: Corneal tissues were obtained from donated pig eyes and organotypically cultured. Tissues were either pretreated with G2 peptide (MPRRRRIRRRQK), control peptide (RVCGSIGKEVLG), or no peptide for 1 hour. The cornea were then scarified and infected topically with HSV-1 KOS at 10^6 PFU for 6, 12, and 36 hour time points. Tissues without both peptide and virus treatment and tissues exposed to only scarification were used as controls. Tissues were snap frozen in liquid nitrogen and stored for immunohistochemical analysis using polyclonal antibodies against HSV-1 antigens. The distribution and intensity of the immunostaining in the corneal epithelium, as well as the epithelial integrity, was assessed using light microscopy. Western blot analysis of homogenized corneal tissue was used to verify differences in viral protein levels.

Results: Immunohistochemical results indicate increased presence of HSV-1 antigens in the epithelium of virally infected cultured corneas following control peptide or no peptide treatment at 6, 12 , and 36 hours postinfection compared to that detected in control, scarified, and G2-pretreated corneas. A relatively increased damage to the corneal epithelium was observed in corneas pretreated with control peptide or no peptide and subsequently virally infected compared to that observed in control, scarified, and G2-pretreated corneas.

Conclusions: An ex vivo model using cultured corneas can be used for HSV-1 infection and therapeutic efficacy determination studies. HSV-1 infection of porcine corneal tissues appears to be inhibited with topical pretreatment with G2 peptide. This suggests an ability of these peptides to inhibit HSV-1 entry when applied as prophylaxis. Further studies are needed to fully evaluate the potential of G2 peptide as a therapeutic option against HSV-1.

Keywords: 545 herpes simplex virus • 482 cornea: epithelium • 661 proteoglycans/glycosaminoglycans  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×